Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments: Running Header: Drug Rebates in Medicare Part D

Keyphrases

• Medicare Part D 100%
• Hepatitis C Treatment 100%
• Out-of-pocket Expenditure 100%
• Rebates 100%
• Patient Costs 100%
• D-excess 100%
• List Price 100%
• Pharmaceutical Products 40%
• High Cost 40%
• Public Health 20%
• New Therapies 20%
• Hepatitis C 20%
• Health Goals 20%
• Policy Advocacy 20%
• Government Spending 20%
• Formulary 20%
• Perverse Incentives 20%
• Acquisition Cost 20%
• Pharmacy Benefit Manager 20%
• Drug Coverage 20%
• Cost Structure 20%
• Drug Selection 20%
• Financial Conflicts of Interest 20%
• Prescription Drug Plans 20%
• Pan-genome 20%
• Prescription Drug Benefits 20%
• Coverage Frequency 20%
• Standard Costs 20%
• Direct-acting Agents 20%
• Consumer Advocates 20%

Economics, Econometrics and Finance

• Cost Structure 100%
• Incentives 100%
• Nutrition Policy 100%
• Public Expenditure 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Hepatitis C 100%
• Prescription Drug 50%